Medicine & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Avicena Group, Inc.
Avicena reports phase III ALS-02 trial results demonstrate trend toward decreased mortality
June 2nd, 2006
The Avicena Group, Inc., (AVGO) a developer of novel pharmaceutical and therapeutic products, announced results of a phase III trial of its drug candidate, ALS-02, for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig disease). Study data showed no statistically significant difference between ALS-02 (5 grams per day) and placebo with regard to the study's primary and secondary endpoints (various measures of muscle strength, muscle fatigue and functional scores). However, in a separate analysis when mortality data was combined and analyzed with mortality data from a second study of ALS-02 previously conducted by the North East ALS Consortium (NEALS), the...
Source: Medicine & Law Weekly (2006-06-02)
|
